Crossmark

Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up

Crossref DOI link: https://doi.org/10.1007/s10549-022-06762-6

Published Online: 2022-12-05

Published Print: 2023-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gao, Song-lin

Wang, Ding-yuan

Wang, Xi

Zhang, Bo

Du, Feng

Ju, Jie

Yue, Jian

Kang, Yi-kun

Wang, Xue

Xu, Bing-he

Yuan, Peng https://orcid.org/0000-0003-4627-8203
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (No. 81672634, No. 82172650)
License Information

Text and Data Mining valid from 2022-12-05

Version of Record valid from 2022-12-05
More Information

Article History

Received: 11 May 2022

Accepted: 6 October 2022

First Online: 5 December 2022

Declarations

:

: The authors declare that they have no conflict of interest.

: This study was approved by the Medical Ethics Review Committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (20/198-2394/272-2468).

: The study is exempt from informed patient consent by the Medical Ethics Review Committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences.

Document is current

Any future updates will be listed below